Stromal cells are involved in organogenic processes by controlling parenchymal cell functions such as migration, proliferation, diff erentiation, and programmed cell death (1) . Among stromal cells, macrophages (MPs) play a major role in the maintenance of tissue homeostasis (2) . In addition to phagocytosis and antigen presentation, these cells play a supportive function in various tissues (2, 3) . However, MPs are renowned for their heterogeneity, as refl ected by the various specialized functions they adopt in diff erent anatomical locations (2, 4) . Many of these activities appear to be opposing in nature (e.g., proinfl ammatory vs. antiinfl ammatory, immunogenic vs. tolerogenic, and tissue-destructive vs. tissuerepair activities) (4) .
Diff erent activation states have been described in vitro for MPs, each being associated with a particular phenotype and function (2, 5) . Classical activation, obtained after LPS/IFN-γ treatment, induces production of proinfl ammatory cytokines and reactive oxygen species. Alternative activation, obtained after IL-4 treatment, increases expression of the mannose receptor (CD206). Deactivation by IL-10 and glucocorticoids induces production of IL-10, TGF-β1, and expression of the scavenger receptor CD163. However, it is not known to Infl ammatory monocytes recruited after skeletal muscle injury switch into antiinfl ammatory macrophages to support myogenesis Macrophages (MPs) are important for skeletal muscle regeneration in vivo and may exert benefi cial effects on myogenic cell growth through mitogenic and antiapoptotic activities in vitro. However, MPs are highly versatile and may exert various, and even opposite, functions depending on their activation state. We studied monocyte (MO)/MP phenotypes and functions during skeletal muscle repair. Selective labeling of circulating MOs by latex beads in CX3CR1 GFP/+ mice showed that injured muscle recruited only CX3CR1 lo /Ly-6C + MOs from blood that exhibited a nondividing, F4/80 lo , proinfl ammatory profi le. Then, within muscle, these cells switched their phenotype to become proliferating antiinfl ammatory CX3CR1 hi / Ly-6C − cells that further differentiated into F4/80 hi MPs. In vitro, phagocytosis of muscle cell debris induced a switch of proinfl ammatory MPs toward an antiinfl ammatory phenotype releasing transforming growth factor 1. In co-cultures, infl ammatory MPs stimulated myogenic cell proliferation, whereas antiinfl ammatory MPs exhibited differentiating activity, assessed by both myogenin expression and fusion into myotubes. Finally, depletion of circulating MOs in CD11b-diphtheria toxin receptor mice at the time of injury totally prevented muscle regeneration, whereas depletion of intramuscular F4/80 hi MPs at later stages reduced the diameter of regenerating fi bers. In conclusion, injured skeletal muscle recruits MOs exhibiting infl ammatory profi les that operate phagocytosis and rapidly convert to antiinfl ammatory MPs that stimulate myogenesis and fi ber growth.
what extent these distinct activation states exist in vivo and whether MP fate is determined forever or whether it remains constantly malleable (2), although several in vitro studies have shown MP adaptation to a changing microenvironment (4, (6) (7) (8) .
An additional degree of complexity is reached with the existence of several subsets of circulating monocytes (MOs). In both the human and mouse, two main MO subsets are present in blood: the main CD14 hi CD16 − (CX3CR1 lo /Ly-6C hi in the mouse) MO subset that invades tissues during acute infl ammation and the CD14 lo CD16 + (CX3CR1 hi /Ly-6C lo in the mouse) MO subset, which is not (or to a lesser extent) recruited during infl ammation (9-13) but is expanded in chronic diseases such as HIV infection, sepsis, tuberculosis, or asthma (14) . Both fate and function of this population remain unclear, because in mouse, it is present in the normal spleen and may correspond to MPs residing in normal tissues (9) .
However, there is growing evidence that they may result from the maturation of Ly-6C hi MOs (11, 15, 16) .
MPs are involved in skeletal muscle repair. Muscle damage induces massive MP infi ltration at the injury site (17, 18) . Partial depletion of MOs/MPs impairs muscle regeneration, whereas reconstitution of bone marrow restores regeneration (19) (20) (21) (22) (23) . Initially limited to phagocytosis of necrotic fi bers, the proregenerative role of MPs has been shown to involve a direct stromal support function (24, 25) . We have previously shown that MO-derived MPs enhance myogenic cell growth (26) . MPs release mitogenic growth factors for myogenic precursor cells (mpcs) and establish cell-cell interactions that protect mpcs from apoptosis (26, 27) . However, little is known about both MO/MP subsets and phenotypes at work during muscle regeneration. Studies in the rat have shown that ED1 + MPs are associated with muscle necrosis, whereas ED2 + (CD163) MPs, regarded as "resident MPs," invade muscle 
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once necrosis has been removed and are associated with regenerative myofi bers (17, 28) . Although the nature of ED1 and ED2 MPs is not characterized, these results suggest that diff erent MP subpopulations are associated with diff erent stages of muscle repair.
In this study, we used in vivo tracing methods to analyze which MO subset was recruited after muscle injury, ex vivo phenotyping analyses to characterize the MO/MP profi le during muscle regeneration, in vitro co-culture experiments to identify which MP phenotype was associated with myogenesis, and sequential in vivo MO/MP depletion studies to evaluate the respective roles of both circulating and i.m. MOs/MPs in skeletal muscle repair.
RESULTS
Two MO/MP subsets are sequentially present during muscle regeneration MOs/MPs collected from skeletal muscle of the CX3CR1 GFP/+ mouse (9, 15) were analyzed according to their GFP and Ly-6C expression during muscle regeneration. Normal muscle contained little CX3CR1 hi /Ly-6C − MOs/MPs ‫002ف(‬ cells/mg of muscle). Notexin was injected in tibialis anterior (TA) muscles to induce the necrosis/regeneration process. As soon as 90 min after injury, CX3CR1 lo /Ly-6C + MOs/MPs were detected in muscle and rapidly invaded the tissue to reach a maximum point at 24 h after injury (25% of CD45 + cells). The CX3CR1 lo /Ly-6C + MO/MP population quickly declined with time, whereas the CX3CR1 hi /Ly-6C − MOs/MPs appeared and continuously increased to reach a plateau at day 7 accounting for 35% of CD45 + cells extracted from muscle at this time point (Fig. 1 A) .
The MO/MP percentage among CD45 + cells is a relative quantifi cation that does not refl ect the amount of MOs/MPs actually present in muscle. Thus, we calculated from these data the total number of extracted GFP + cells per milligram of muscle. Results indicated that the extent of the two MO/MP waves was diff erent (Fig. 1 B) , and this was confi rmed by histological examination (Fig. 1 C) . During the fi rst 2 d, as injured myofi bers became necrotic, 2,000 to 3,500 GFP + cells/mg of muscle were counted. At 4 and 7 d, when myogenic cells proliferated and further diff erentiated (Fig. 1 C) , fi ve-to sixfold more GFP + MOs/MPs were found in muscle (12,000-16,000 cells/mg; Fig. 1 B) . 10 d after injury, when centrally nucleated fi bers were visible throughout the injured area ( Fig. 1 C) , the amount of GFP + cells had dramatically declined to reach <2,000 GFP + cells/mg of tissue (Fig. 1 B) .
CX3CR1 lo /Ly-6C + and CX3CR1 hi /Ly-6C − MO/MP populations display distinct proliferative and infl ammatory profi les Between days 1 and 4 after injury, the number of Ly-6C − MOs/MPs increased 20-fold, while the number of Ly-6C + MOs/MPs increased twofold (Fig. 1 B) . We analyzed proliferation of both subsets that were isolated from regenerating muscle by cell sorting (Fig. 2 A) . Ki67 labeling showed that Ly-6C + MOs/MPs never proliferated, whereas Ly-6C − MOs/MPs partially entered into cell cycle from day 2, and the number of proliferating cells doubled at day 4 and further decreased by twofold at day 7 (Fig. 2 B) .
To examine the infl ammatory profi le of the two MO/MP populations, we analyzed cytokine expression of isolated Ly-6C − and Ly-6C + MOs/MPs at day 4 after injury by RT-PCR. Results showed that Ly-6C + MOs/MPs expressed IL-1β and, to a lesser extent, TNF-α transcripts more strongly than Ly-6C − MOs/MPs (Fig. 2 C) . Conversely, Ly-6C − MOs/MPs expressed TGF-β1 and IL-10 more strongly than Ly-6C + MOs/MPs (Fig. 2 C) , indicating that Ly-6C + MOs/ MPs had an infl ammatory profi le and Ly-6C − MOs/MPs had an antiinfl ammatory profi le.
Injured muscle only recruits CX3CR1 lo /Ly-6C + MOs/MPs that subsequently switch into antiinfl ammatory CX3CR1 hi / Ly-6C − MOs/MPs and differentiate into MPs We labeled each circulating subset with fl uorescent latex beads (LXs) before injury, as previously described (12, 15) . Labeling of MOs does not alter their migratory capacities (12) . After i.v. LX injection, circulating LX + cells were CX3CR1 hi /Ly-6C − MOs (Fig. 3 A, top, blood) ; LX + cells were never detected in muscle after injury (Fig. 3 A, top, muscle), indicating that Ly-6C − MOs/MPs appearing in muscle at day 2 were not recruited from blood. After clodronate-encapsulated liposome (clo-lip) injection followed by LX injection, circulating LX + cells were CX3CR1 lo /Ly-6C + MOs, as previously described (15) . 36 h after notexin injection, LX + cells were still Ly-6C + MOs (95%) in the blood (Fig. 3 A, bottom, blood), while LX + cells present within muscle were both Ly-6C + and Ly-6C − (38 ± 2 and 61 ± 3%, respectively, based on three experiments; Forward and side scatter of the two MO/MP subsets isolated at day 7 after injury showed that Ly-6C − MOs/MPs had higher side scatter and were larger than Ly-6C + MOs/MPs (Fig. 3 C) , in accordance with a maturation of the Ly-6C − subset. Analysis of diff erentiation markers showed that Ly-6C − MOs/MPs expressed CD11c and higher levels of F4/80 (Fig. 3 C) . Nearly all (> 90%) F4/80 + cells were CD11c + and I-A b+ , and no positivity was observed for the dendritic cell marker DEC-205 (unpublished data). These results show that, contrary to Ly-6C + MOs/MPs, Ly-6C − MOs/MPs exhibited high levels of MP diff erentiation markers.
Collectively, these results suggest that after muscle injury, infl ammatory Ly-6C + MOs are recruited from blood, convert to antiinfl ammatory Ly-6C − MOs/MPs that proliferate in situ, and further diff erentiate into mature MPs.
Phagocytosis of muscle cell debris participates in MP phenotype transition
To study interactions between MPs and myogenic cells possibly involved in MP phenotype transition, we used in vitro human cell co-cultures. Indeed, in vitro pro-and antiinfl ammatory MP activation states described in humans most likely correspond to Ly-6C + and Ly-6C − MO/MP profi les found in regenerating mouse muscle. Consistently, LPS/IFN-γ treatment of human MPs induced TNF-α (P < 0.05) and IL-1β (P < 0.05) secretion (Fig. 4 A) , whereas dexamethasone (DEX)/IL-10 treatment induced IL-10 (P < 0.05) secretion (Fig. 4 A) , as previously shown (36, 37) . Because diff erentiating muscle cells secrete IL-4 (38), a key inducer of alternative activation of MPs (5), we tested IL-4 treatment, 
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which induced TGF-β1 secretion (Fig. 4 A) , as previously shown (39) .
As a major role of MPs is to operate phagocytosis of dead cells, we evaluated the eff ect of phagocytosis of muscle cell debris on the MP infl ammatory profi le. Upon phagocytosis of necrotic mpcs, LPS/IFN-γ-treated MPs both decreased their TNF-α secretion (P < 0.05) and increased their TGF-β1 secretion (P < 0.03; Fig. 4 B) . We attempted to inhibit phagocytosis of proinfl ammatory MPs by colchicine (40) , cytochalasin D (41) , and recombinant Annexin V (42). Colchicine failed to inhibit phagocytosis, and MPs changed their cytokine secretion upon mpc debris phagocytosis, as in untreated cells (Fig. 4 C) . Conversely, phagocytosis was inhibited in the presence of cytochalasin D or recombinant Annexin V; in these conditions, TNF-α and TGF-β1 secretion did not change in the presence of mpc debris (Fig. 4 C) . These data indicate that phagocytosis of mpc debris induced a switch of the MP phenotype toward an antiinfl ammatory profi le, as previously shown for other cell types (43) (44) (45) (46) .
We also evaluated whether interactions with living mpcs may infl uence MP phenotype. Neither addition of mpcs to previously activated MPs nor addition of mpcs before MP activation substantially altered the MP phenotype (unpublished data). These data show that mpcs neither modifi ed the MP activation state nor prevented acquisition of any given MP phenotype.
Infl ammatory MPs increase mpc growth, whereas antiinfl ammatory MPs stimulate their differentiation
In co-culture experiments, we analyzed mpc behavior depending on MP activation state. We have previously shown that untreated MPs stimulate mpc growth and proliferation (26) . As shown in Fig. 5 , mpc diff erentiation (Fig. 5 C) and fusion (Fig. 5 D) were also increased by untreated MPs (P ≤ 0.05). LPS/IFN-γ-treated MPs were more potent in enhancing mpc growth (63%; P < 0.05; Fig. 5 A) , and accordingly, they enhanced mpc proliferation, as shown by increased BrdU incorporation (25%; P < 0.05; Fig. 5 B) . Inversely, both myogenin expression (Fig. 5 C) and myotube formation (Fig. 5 D) were strongly reduced (58 and 68%, respectively; P < 0.05), indicating an inhibition of diff erentiation by infl ammatory MPs. IL-4-treated MPs slightly reduced mpc proliferation (14%; P < 0.05; Fig. 5 B) , whereas they stimulated myogenin expression (28%; P < 0.05; Fig. 5 C) and stimulated myotube formation (158%; P < 0.05; Fig. 5 D) compared with untreated MPs. DEX/IL-10-treated MPs did not stimulate growth (Fig. 5 A) and proliferation (Fig. 5 B) compared with untreated MPs but presented a strong prodiff erentiating activity, as assessed by increased myogenin expression (52%; P < 0.05; Fig. 5 C) and increased myotube formation (136%; P < 0.01; Fig. 5 D) . These results strongly suggest that the activation state of MPs may monitor the myogenic process.
MO/MP presence is mandatory for skeletal muscle regeneration
We took advantage of the CD11b-diphtheria toxin receptor (DTR) mouse to study the respective roles of MO/MP subsets during muscle regeneration in vivo, because i.m. injection of clo-lip is toxic for myogenic cells (unpublished data). In CD11b-DTR mice, MOs (and possibly tissue MPs, depending on the way of injection) are depleted after DT injection (47) . After a single i.v. DT injection, circulating MO loss occurred from 6 h and reached a maximum at 12 h, which lasted 12 h longer, with subsequent restoration and normalization at 48 h (Fig. 6 A) . At maximum depletion, 75-80% of cells in the MO gate had disappeared (Fig. 6 A) , as did F4/80 + , CD11b + , and Ly6C + cells (not depicted). The time course of postinjury muscle regeneration in untreated CD11b-DTR mice was similar to that of the C57BL/6 mouse shown in Fig. 1 until day 4 , but centrally nucleated myofi bers appeared earlier in CD11b-DTR than in C57BL/6 mice (day 7 vs. 10; Fig. 6 B) . When DT was simultaneously injected at (Fig. 6 C) or 12 h before (Fig. 6 D) muscle injury, necrotic fi bers were removed more slowly, and regeneration was impaired with the appearance of adipose cells (Fig. 6, C  and D; and Fig. 7) . After double DT injection, both 12 h before and simultaneously at notexin injection (which induced a MO depletion lasting 0-24 h after injury), almost no MO/ MP infi ltration was observed (Fig. 6 E) . None of the hallmarks of regeneration were detected, and persistence of necrotic fi bers was observed until day 7 ( Fig. 6 E and Fig. 7) , although circulating MOs reappeared in the circulation from day 2 after injury (not depicted). When DT was injected 4 d after notexin, no diff erence was observed compared with the control (Fig. 6 B and Fig. 7) , indicating that circulating MOs were no longer recruited into muscle at this time. Notably, i.v.-injected DT did not notably aff ect i.m. MOs/MPs, as shown by unchanged expression of both F4/80 and CD11b by CD45 + cells isolated from muscle ( Fig. 6 F, inset) .
We attempted to target i.m. antiinfl ammatory MOs/MPs at a time when phagocytosis of necrotic myofi bers is fi nished (Fig. 6 B and Fig. 7 A) . To assess MP depletion in muscle, fl ow cytometric analysis of CD45 + cells was performed 24 h after a single i.m. DT injection. The total number of F4/80 + cells present in muscle was diminished by 25% after DT injection (especially F4/80 hi cells, which were diminished by 75%; P < 0.05; Fig. 8 A) , indicating that these diff erentiated FSC hi F4/80 hi MPs, corresponding to Ly-6C − MPs, were targeted by DT. However, the total number of CD45 + cells increased by twofold in DT-versus PBS-injected muscle (Fig.  8 A) , indicating that i.m. DT injection induced a secondary infl ammation accompanied by the recruitment of F4/80 − leukocytes (likely neutrophiles and F4/80 lo/− MOs). Consistently, histological examination of whole TA muscle 4-5 d later showed an area in which new cycles of regeneration were visible, as assessed by the presence of necrotic and basophilic fi bers (Fig. 8 B, arrow) . This area was restricted to the site of needle puncture and was therefore excluded from the analysis to avoid counting of small regenerating myofi bers coming from the secondary lesion (Fig. 8 B) . The diameter of centrally nucleated regenerating myofi bers was evaluated in the rest of the TA and was found to be reduced by 41% in DT-versus PBS-injected muscle (30.8 vs. 18.2 μm, respectively; P < 0.001; Fig. 8 C) .
D I S C U S S I O N
In the present study, we have shown that (a) injured skeletal muscle selectively recruits Ly-6C + circulating MOs that exhibit an infl ammatory profi le; (b) within muscle, Ly-6C + MOs switch their phenotype to acquire an antiinfl ammatory profi le, with phagocytosis of muscle cell debris being most likely involved in this transition; (c) as necrosis disappears from the injured area, antiinfl ammatory Ly-6C − MOs/MPs proliferate and further diff erentiate into MPs; (d) in vitro, infl ammatory MPs enhance myogenic cell proliferation and repress their diff erentiation, whereas antiinfl ammatory MPs stimulate myogenesis and fusion; and (e) in vivo depletion of circulating MOs at the time of injury totally prevents muscle regeneration, whereas later depletion of i.m. MPs decreases the diameter of regenerating fi bers.
It has been shown that the CX3CR1 lo /Ly-6C + MO population is recruited in injured or infl amed tissues (9, 13, 48) . Our experiments using LX-labeled circulating MOs showed that CX3CR1 lo /Ly-6C + MOs were selectively recruited rapidly after muscle injury. Mouse CX3CR1 lo /Ly-6C + MOs and their human analogues bear several chemokine receptors, including CC chemokine receptor (CCR) 2, CCR1, CCR4, CCR7, CXC chemokine receptor 1, and CXC chemokine receptor 2 (9). The corresponding chemokines are expressed by muscle tissue during the fi rst days after injury (the cytokine expression profi le is available at http://pepr .cnmcresearch.org) (22, 49, 50) . Monocyte chemoattractant protein-1 has been particularly involved in MO recruitment by injured muscle (19, 20) . We did not evidence recruitment of CX3CR1 hi /Ly-6C − MOs from blood to muscle. Moreover, transient depletion of circulating MOs during the fi rst 0-24 h after muscle injury showed no subsequent MP infi ltration despite reconstitution of the pool of circulating MOs. This suggests that CX3CR1 lo /Ly-6C + MO/MP recruitment takes place early after injury (i.e., within 2-3 d after injury).
Our experiments showed that initially LX-labeled CX3CR1 lo /Ly-6C + MOs converted to CX3CR1 hi /Ly-6C − MOs/MPs from day 2 after injury, indicating a phenotype transition of MOs/MPs within muscle. Consistently, MP differentiation markers were weakly expressed by CX3CR1 lo /Ly-6C + MOs/MPs and markedly expressed by CX3CR1 hi / Ly-6C − MOs/MPs (see below). We propose that CX3CR1 lo / Ly-6C + cells, which exhibit an infl ammatory phenotype (expressing TNF-α and IL-1β), progressively lose Ly-6C expression while converting to antiinfl ammatory MOs/MPs (expressing TGF-β1 and IL-10). These data are in accordance with the cytokine mRNA analysis of postinjured muscle extract (available at http://pepr.cnmcresearch.org) (51): TNF-α and IL-1β expression peaks at days 2-3 after injury, whereas IL-10 and TGF-β1 expression increases from day 2 after injury and is maintained throughout regeneration. MP phenotype conversion observed in skeletal muscle further supports previous in vitro evidence that MPs are capable of rapid adaptation to changing environments (4, (6) (7) (8) and in vivo demonstration that MPs alter their phenotype according to their tissue environment (52) .
MPs participate in both amplifi cation of infl ammation at the time of injury and down-regulation of the infl ammatory response to avoid excess tissue damage (31, 53, 54) . MP stop signals associated with the resolution of infl ammation include induction of negative regulators of infl ammation in MPs by environmental cues and nonphlogistic phagocytosis. As shown herein, both likely operate during skeletal muscle regeneration. SLPI is considered as a brake on the response of MPs to infl ammation (29, 31) . Its expression is induced by LPS and IL-6 and leads to inhibition of NO and TNF-α production (30) . In vivo, the highest SLPI synthesis occurs during the proinfl ammatory phase and, thus, anticipates an increase in TGF-β1 and IL-10 production (32). Accordingly, we have shown that CX3CR1 lo /Ly-6C + MOs/MPs expressed more SLPI than CX3CR1 hi /Ly-6C − cells. Another marker associated with the resolution of infl ammation by 
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MPs is PPAR-γ. Fatty acids and prostaglandin metabolites bind to PPAR-γ in activated MPs, which triggers inhibition of both inducible NO synthase and release of proinfl ammatory cytokines (33, 35) , thus conferring antiinfl ammatory pro perties to PPAR-γ (34) . In this paper, we showed that antiinfl ammatory CX3CR1 hi /Ly-6C − MOs/MPs strongly expressed PPAR-γ. Nonphlogistic phagocytosis by MPs is another signal for switching to healing (31) . Binding and phagocytosis of apoptotic cells inhibit secretion of proinfl ammatory mediators and stimulate secretion of TGF-β1 and IL-10 by infl ammatory MPs (43) (44) (45) (46) . Induction of an antiinfl ammatory process by phagocytosis of necrotic cells depends on the cell type ingested (42, 43, 55) . We showed that both unstimulated and infl ammatory MPs adopted an antiinfl ammatory profi le upon phagocytosis of necrotic muscle cell debris and that inhibition of MP phagocytosis prevented this phenotype switch. Collectively, these results strongly suggest that recruited infl ammatory CX3CR1 lo /Ly-6C + MOs/ MPs convert to antiinfl ammatory CX3CR1 hi /Ly-6C − MOs/ MPs upon both ingestion of muscle cell debris and expression of stop signals extinguishing infl ammation.
Our results showed that once switched, CX3CR1 hi /Ly-6C − MOs/MPs actively proliferated, therefore contributing to the large amounts of MOs/MPs observed in muscle at days 4-7 after injury. In vitro, MP proliferation is inhibited by infl ammatory mediators (LPS, IFN-γ, NO, and IL-6) and is stimulated by TGF-β1 (56) (57) (58) . Thus, proliferation of recruited MOs/MPs may be caused by changes in their environment, although as yet unknown mechanisms related to the change of phenotype cannot be excluded. Later during muscle regeneration (day 7), CX3CR1 hi /Ly-6C − MO/MP proliferation slowed down simultaneously with the complete diff erentiation into MPs, as shown by their strong F4/80 expression (59) . Almost all F4/80 + cells were also positive for CD11c and MHCII, as previously observed after infl ammation in various organs (60, 61) , and were DEC-205 − . In the blood, Ly-6C − MOs, which come from Ly-6C + cells, are also CD11c + (12) . Therefore, the appearance of CD11c + cells in the muscle may be a recapitulation of conversion from Ly-6C + /CD11c − to Ly-6C − /CD11c + MOs within the tissue. Thus, proliferating CX3CR1 hi /Ly-6C − MOs/MPs and diff erentiating CX3CR1 hi /Ly-6C − MPs are associated with the regenerative phase of muscle repair.
Depending on the context, MPs may have supportive or deleterious eff ects on cells: in chronic diseases, including those aff ecting skeletal muscle, MPs are deleterious (62, 63), whereas they support tissue repair in muscle and other various tissues, including the liver, brain, peripheral nerve, and epithelium (19) (20) (21) (22) (64) (65) (66) (67) . With the exception of regulation of infl ammation, studies documenting a direct role of MPs on cell behavior are scant and include intestinal progenitor proliferation (65) , erythroblast proliferation and maturation (68) , and oligodendrocytic diff erentiation and myelination (69) . In vitro studies have shown that the MP activation state may direct neural progenitor diff erentiation toward either neurogenesis or oligodendrogenesis (70) . Our results substantiate the view that MP function may be related to an activation state. In coculture experiments, infl ammatory MPs (the counterpart of infl ammatory CX3CR1 lo /Ly-6C + cells observed in vivo) stimulated mpc proliferation and inhibited their diff erentiation. Inversely, IL-4 treated and antiinfl ammatory MPs exhibited a strong diff erentiating activity on mpcs, assessed by both stimulation of myogenic program and increase of fusion into multinucleated cells. Molecular mechanisms involved in these processes are currently under investigation. It is likely that cytokines released by activated MPs infl uence myogenic cell behavior: TNF-α is mitogenic for myoblasts and inhibits their diff erentiation (71, 72) , IL-1β impairs myogenic diff erentiation through insulin-like growth factor-1 (73) , and in vitro eff ects of TGF-β1 are more controversial, although in vivo neutralization of TGF-β1 in regenerating muscle was shown to reduce the diameter of regenerating myofi bers (74) . Beyond cytokines, cyclooxygenase 2 and its metabolites may also play a role, as they were shown to be fusogenic and necessary for good muscle repair (75) (76) (77) .
Previous in vivo studies using diff erent injury models have shown that partial reduction of MO/MP entry into injured muscle hinders muscle regeneration, as shown by a delay in the appearance of regenerating myofi bers and the persistence of intermuscular adipocytes (19) (20) (21) (22) . We observed similar features upon partial inhibition of MO recruitment in toxic-induced muscle regeneration. Moreover, when nearly no MO/MP was allowed to enter damaged muscle, myofibers remained in the necrotic state, indicating the indispensable role of MPs in muscle repair. Interestingly, despite the normalized level of circulating MOs from day 2 after injury, no delayed recruitment was observed, suggesting that signals governing MO recruitment are only transiently expressed by the damaged tissue, as was recently documented in ultravioletinjured skin (48) . Accordingly, depletion of circulating MOs at day 4 after injury had no eff ect on muscle regeneration. On the other hand, depletion of i.m. antiinfl ammatory F4/80 hi MOs/MPs at the time of regeneration (i.e., once phago cytosis of necrotic myofi bers is achieved) reduced the diameter of the centrally nucleated regenerating myofi bers, indicating that these MOs/MPs were involved in fi ber growth, in accordance with our in vitro data.
In conclusion, our data demonstrate a phenotype transition operated by recruited MOs/MPs during resolution of infl ammation and tissue repair, which is associated with changes in their functions. We propose sequential involvements of these two phenotypically distinct MP populations during skeletal muscle repair as follows: within the fi rst 24-48 h after injury, skeletal muscle recruits infl ammatory circulating MOs, which stimulate myogenic cell proliferation and prevent their diff erentiation. While they are exposed to an infl ammatory environment and operate phagocytosis of muscle cell debris, infl ammatory MOs/MPs convert to antiinfl ammatory MOs/MPs. As phagocytosis of necrotic myofi bers is fi nished, these antiinfl ammatory MOs/MPs actively proliferate and further diff erentiate into antiinfl ammatory MPs that sustain myogenic diff erentiation and myofi ber growth in addition to their protective eff ect on diff erentiating myotubes (27) and their eff ect on fi ber membrane repair (78) .
MATERIALS AND METHODS
Animals. C57BL/6, CX3CR1 gfp/+ (9), and CD11b-DTR (provided by J.S. Duffi eld, Harvard Medical School, Boston, MA) (47) mice were bred and used according to French legislation. Experiments were conducted at 4-8 wk of age.
Muscle injury and muscle preparation. 10 μl notexin (25 μg/ml in PBS; Latoxan) was injected in the TA. For histological analysis, muscles were prepared as previously described (27) . Quantitative analysis of muscle regeneration was performed on the entire injured area: approximately seven fi elds (20× objective; PL Flustar; Carl Zeiss MicroImaging, Inc.) were analyzed in each mouse, representing 300-400 fi bers per mouse. Myofi ber diameter was evaluated after collagen IV immunolabeling (see Immunolabeling) on approximately seven fi elds (20× objective) in each mouse. The small diameter of only centrally nucleated myofi bers was evaluated in late-regenerating muscle (nonhatched area in Fig. 8 B) with Axiovision 4.6 software (Carl Zeiss MicroImaging, Inc.), representing 250-350 fi bers per mouse. In PBSinjected mice, the punctured fascicule was omitted from analysis.
Isolation of MOs/MPs from muscle. Fascia of the TA was removed. Muscles were dissociated in DMEM containing collagenase B 0.2% (Roche Diagnostics GmbH) and trypsine-EDTA 0.2% at 37°C for 45 min twice, fi ltered, and counted. CD45+ cells were isolated using magnetic sorting (Miltenyi Biotec) and stained with PE-or PC5-conjugated anti-Gr1 antibody (which reacts with Ly-6C and Ly-6G, but only Ly-6C is expressed by MOs; eBioscience). Cells were sorted using a cell sorter (Epics Elite; Beckman Coulter). Populations presenting >90% purity were used. In some experiments, PE-conjugated CD11c, I-A b (BD Biosciences) and F4/80 (AbD Serotec) antibodies were used. Analysis was performed with a cytometer (FACSCalibur; BD Biosciences).
Labeling of blood MOs. Labeling of circulating MOs was performed exactly as previously described (15) with plain microspheres (Fluoresbrite Polychromatic Red Microspheres 0.5μm, 2.5% solids; PolySciences, Inc.) and clo-lip, which were prepared as previously described (79) . Clodronate was a gift of Roche Diagnostics GmbH.
ARTICLE
Depletion of circulating MOs and i.m. MPs. 12 ng/g DT was i.v. injected into CD11b-DTR mice. Blood was retroorbitally harvested at various times after injection, and cells were labeled with anti-CD11b, anti-Gr1, and F4/80 antibody and analyzed by fl ow cytometry. Because of high interindividual variations (3-12% of PBMCs), the number of circulating MOs in control mice was normalized to 5% of PBMCs for each series (mean calculated with >25 mice). To deplete infi ltrated MOs/MPs, 25 ng/g DT in <10 μl was i.m. injected at days 5 and 6 after injury. Controls included injection of PBS.
Immunolabeling. Muscle slides were incubated with anticollagen IV antibody (1:50; Chemicon International, Inc.) revealed with Cy5-conjugated anti-rabbit antibody. Mouse-sorted cells were centrifugated on slides and labeled with 1 μg/ml anti-Ki67 antibody (Abcam plc), revealed with FITCconjugated anti-rabbit antibody. Cultured human mpcs were incubated with 60 μg/ml antidesmin antibody (Abcam plc), revealed by a Cy3-conjugated antirabbit antibody, and with 10 μg/ml antimyogenin antibody (BD Biosciences), revealed by a biotinylated anti-mouse (Vector Laboratories) and by dichlorotriazinglaminofl uorescein-streptavidin (Beckman Coulter). Controls included incubation with whole rabbit or mouse IgGs. Other secondary antibodies and IgGs were obtained from Jackson ImmunoResearch Laboratories.
RT-PCR.
Total RNA was prepared from sorted cells using the RNeasy mini kit (QIAGEN). 0.5 μg of total RNA was reverse transcripted using Superscript II reverse transcriptase and amplifi ed with a platinum Taq DNA polymerase (Invitrogen) and the following specifi c primers (sense and antisense, respectively): β2 microglobulin, 5′-C A G T T C C A C C C G CCTCAC-3′ and
5′-C A C A T G T C T C G A T C C C A G -3′; TNF-α, 5′-T T C C A G A T T C T T C-C C T G A G G T -3′ and 5′-T A A G C A A A A G A G G A G G C A A C A -3′; IL-1β, 5′-T G A C G T T C C C A T T A G A C A A C T G -3′ and 5′-C C G T C T T T C A T T A-C A C A G G A C A -3′; TGF-β1, 5′-G A G A C G G A A T A C A G G G C T T T C -3′ and 5′-T C T C T G T G G A G C T G A A G C A A T -3′; IL-10, 5′-A C C A G C T G G A C A-A C A T A C T G C -3′ and 5′-T C A C T C T T C A C C T G C T C C A C T -3′; SLPI, 5′-C C T T A A G C T T G A G A A G C C A C A -3′ and 5′-A G C A C T T G T A T T T G-C C G T C A C ; and PPAR-γ, 5′-A A G A G C T G A C C C A A T G G T T G -3′ and 5′-G G A T C C G G C A G T T A A G A T C A -3′
. Amplifi cation was performed at 94°C, 60°C, and 72°C for 1 min for each step for 30 cycles. 10 μl of amplification products was subjected to electrophoresis on a 2% agarose gel containing ethidium bromide for visualization. Quantifi cation was performed by using Image software (Scion).
Human mpc culture. Culture media components were purchased from Invitrogen. Human mpcs were cultured from muscle samples at the time of corrective surgery, in conformity with French legislation (Code de la Santé Publique, livre II), as previously described (26) .
Human MP cell culture. MPs were diff erentiated from MOs isolated from human blood, as previously described (26) . Diff erentiated MPs were further cultured in either RPMI 1640 medium containing 15% FBS or advanced RPMI 1640 medium containing 0.5% FBS (supplemented with 1% sodium pyruvate, 10 mM Hepes, 50 μM β-mercaptoethanol, 1% nonessential amino acids, 100× 1% vitamins). MPs were treated, or not, for 48 h with either 1 μg/ml LPS (Sigma-Aldrich) and 10 ng/ml IFN-γ (PeproTech), or 10 ng/ml IL-4 (PeproTech) or 80 ng/ml DEX (Sigma-Aldrich) and 10 ng/ml IL-10 (PeproTech).
Phagocytosis. mpc necrosis was induced by H 2 O treatment for 1 h at 37°C. 100% of cells were propidium iodide positive. Necrotic mpcs were seeded on MPs (fi ve dead mpcs for one MP) for 3 h at 37°C. MP cultures were washed three times to remove noningested material and further cultured in serum-free advanced RPMI 1640 supplemented medium over 24 h to make conditioned media. In some experiments, cells were treated, as previously described, with 10 μg/ml colchicine (Sigma-Aldrich) (40), 1 μg/ml cytochalasin D (Sigma-Aldrich) (41), or 40 μg/ml recombinant Annexin V (BD Biosciences) (42) . Phagocytosis was quantifi ed in the same conditions after incubation with fl uorescent microspheres (as described in Labeling of blood MOs). The number of LX + cells was quantifi ed under an inverted microscope and expressed as the percentage of total cells.
Co-cultures. mpcs were plated on previously prepared MP cultures (3:1 MP/mpc ratio) in advanced RPMI 1640 supplemented medium, except in some experiments in which MPs and mpcs were seeded together before MP treatment was applied, as described in Human MP cell culture. mpc behavior. mpc growth was evaluated as previously described (26) . mpc proliferation was estimated by BrdU incorporation (Roche Diagnostics GmbH). mpc diff erentiation was evaluated by counting the number of myogenin + cells among desmin + cells. mpc fusion was estimated by counting the number of nuclei per myotube.
Statistical analyses.
All experiments were performed using at least three diff erent cultures or animals in independent experiments. The Student's t test was used for statistical analyses. P < 0.05 was considered signifi cant.
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